List of insiders holdings for BeiGene Ltd.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| HHLR ADVISORS LTD. HILLHOUSE INVESTMENT MANAGEMENT LTD. 10% Owner | 2023-06-15 19:25:01 | 0 142,888,241 | 142,888,241 | Form 4 |
| BAKER BROS. ADVISORS LP 14159 L.P. Baker Bros. Advisors (GP) LLC BAKER JULIAN BAKER FELIX 667 L.P. Baker Brothers Life Sciences LP Director 10% Owner | 2023-11-14 17:18:44 | 138,678,037 0 | 138,678,037 | Form 13D |
| OYLER JOHN Chief Executive Officer | 2024-06-26 17:22:41 | 1,759,108 46,190,763 | 47,949,871 | Form 4 |
| CB Biotech Investment Ltd CPEChina Fund L.P. CITIC PE Associates L.P. CITIC PE Funds Ltd 10% Owner | 2016-02-09 20:07:35 | 19,601,138 0 | 19,601,138 | Form 4 |
| AMGEN INC 10% Owner | 2021-09-13 19:27:07 | 18,943,802 0 | 18,943,802 | Form 4 |
| Wang Xiaodong Chair, Scientific Advisory Brd | 2024-06-07 16:56:19 | 5,979,087 5,186,590 | 11,165,677 | Form 4 |
| BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner | 2024-06-07 16:03:29 | 20,838 10,831,600 | 10,852,438 | Form 4 |
| Glazer Donald W. Director | 2024-06-07 16:58:01 | 2,752,615 0 | 2,752,615 | Form 4 |
| Li Ji EVP and Gl. Head of Bus. Dev. | 2018-03-02 18:41:22 | 2,721,000 0 | 2,721,000 | Form 4 |
| Peterson Amy C. CMO, Immuno-oncology | 2018-12-19 18:34:10 | 1,966,402 0 | 1,966,402 | Form 4 |
| Wang Lai Global Head of R&D | 2024-06-26 17:25:16 | 1,724,697 58,188 | 1,782,885 | Form 4 |
| Liang Howard CFO & Chief Strategy Officer | 2021-06-30 16:45:49 | 1,553,149 0 | 1,553,149 | Form 4 |
| Wu Xiaobin President, COO & GM China | 2024-06-26 17:24:35 | 1,219,945 4000 | 1,223,945 | Form 4 |
| Yang Jianxin Sr. VP, Head of Clinical Dev. | 2016-07-15 16:34:25 | 825,000 0 | 825,000 | Form 4 |
| Yan Wendy Xiaojun Sr. VP, Head of Reg. Affairs | 2016-07-15 16:30:50 | 825,000 0 | 825,000 | Form 4 |
| Wang Julia Aijun Chief Financial Officer | 2024-07-03 17:05:32 | 426,595 0 | 426,595 | Form 4 |
| Huang Jane CMO, Hematology | 2021-12-16 17:50:15 | 371,331 0 | 371,331 | Form 4 |
| Lee Chan Henry SVP, General Counsel | 2024-06-20 17:24:29 | 263,692 0 | 263,692 | Form 4 |
| Tang Ke Director | 2017-04-21 16:42:20 | 199,992 0 | 199,992 | Form 4 |
| Yuan RuiRong Chief Medical Officer | 2016-02-09 20:08:35 | 130,000 0 | 130,000 | Form 4 |
| Malley Thomas Director | 2023-06-20 19:00:29 | 103,671 0 | 103,671 | Form 4 |
| HOOPER ANTHONY C Director | 2024-06-07 17:00:40 | 87,906 0 | 87,906 | Form 4 |
| Sanders Corazon (Corsee) D. Director | 2024-06-07 16:55:28 | 80,392 0 | 80,392 | Form 4 |
| Yi Qingqing Director | 2024-06-07 16:31:17 | 80,106 0 | 80,106 | Form 4 |
| Riva Alessandro Director | 2024-06-07 16:57:19 | 80,106 0 | 80,106 | Form 4 |
| Dugan Margaret Director | 2024-06-07 17:02:26 | 80,106 0 | 80,106 | Form 4 |
| Ball Titus B. Principal Accounting Officer | 2024-06-07 17:05:24 | 63,245 0 | 63,245 | Form 4 |
| BRANDICOURT OLIVIER Director | 2024-06-07 17:01:38 | 50,492 0 | 50,492 | Form 4 |
| Chen Timothy Yung-Cheng Director | 2021-06-21 16:42:08 | 25,298 0 | 25,298 | Form 4 |
| su Jingshyh S Director | 2021-06-21 16:34:12 | 25,298 0 | 25,298 | Form 4 |
| KRISHANA RANJEEV Director | 2016-02-02 19:14:15 | 0 0 | 0 | Form 3 |
| Rosenberg Aaron Chief Financial Officer | 2024-07-24 17:23:32 | 0 0 | 0 | Form 3 |
| Merck & Co. Inc. Merck Sharp & Dohme Corp. Merck Sharp & Dohme Research GmbH 10% Owner | 2018-02-13 16:29:07 | 0 0 | 0 | Form 13G |
| GOLLER MICHAEL Director | 2016-02-02 19:40:27 | 0 0 | 0 | Form 3 |